Clinical trialNCT07161544RecruitingPhase 1/PHASE2Interventional

A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

SponsorAAVantgarde Bio SrlEnrollment75Stargardt Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the ABCA4 gene. The study will also assess initial efficacy following AAVB-039 administration.

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United Kingdom

Moorfields Eye Hospital Nhs Foundation Trust
London, England, United Kingdom
Prof. Michel Michaelides
Recruiting
the Retina Clinic
London, England, United Kingdom
Prof. Paulo-Eduardo Stanga
Recruiting

United States

Associated Retina Consultants
Phoenix, Arizona, United States
Dr. Benjamin Bakall
Recruiting
Retina Vitreous Associates Medical Group
Los Angeles, California, United States
Dr. David Liao
Recruiting
University of Florida Health Science Center
Jacksonville, Florida, United States
Dr. Sandeep Grover
Recruiting
Mayo Clinic
Rochester, Minnesota, United States
Dr. Brittni Scruggs
Recruiting
Retina Consultants of Texas
Bellaire, Texas, United States
Dr. Kenneth Fan
Recruiting
Retina Foundation of the Southwest
Dallas, Texas, United States
Dr. Karl Csaky
Recruiting
University of Utah
Salt Lake City, Utah, United States
Dr. Paul Bernstein
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AAVB-039

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 Sept 2025
Primary completion: 31 Jul 2032
Completion: 31 Jul 2032
Last update posted: 30 Jul 2026
Registered enrollment: 75
Registry id: NCT07161544

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.